Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

Objective To investigate the efficacy, safety and immunogenicity of PF-06438179/GP1111 (PF-SZ-IFX) compared with European reference infliximab (Remicade®; ref-IFX) in patients with moderate-to-severe, active rheumatoid arthritis after continued long-term use of PF-SZ-IFX, and in patients who were sw...

Full description

Saved in:
Bibliographic Details
Main Authors: Goran Babic, Hideto Kameda, Rieke Alten, Bogdan Batko, Tomas Hala, Sebastiao C Radominski, Vira Tseluyko, Carol Cronenberger, Sarah Hackley, Muhammad Rehman, Oliver von Richter, Min Zhang, Stanley Cohen
Format: Article
Language:English
Published: BMJ Publishing Group 2019-05-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/5/1/e000876.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items